BLAINJECTIONINJECTABLE
Approved
Jul 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
8
Mechanism of Action
Fusion Protein Inhibitors
Pharmacologic Class:
Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody
Clinical Trials (5)
A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea
Started Oct 2025
3,000 enrolled
Respiratory Syncytial Virus
Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India
Started Jul 2025
110 enrolled
RSV Immunization
BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)
Started Apr 2024
49,680 enrolled
Respiratory Syncytial Virus
A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab
Started Jul 2023
33 enrolled
Respiratory Syncytial Virus Infections
Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life
Started Aug 2022
8,057 enrolled
RSV ImmunizationHealthy Volunteer